DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of TZIELD™ (teplizumab-mzwv) and Updates Long-Term Cash Receipts Outlook

– Transaction adds a ground-breaking type 1 diabetes therapy to DRI’s expanding portfolio – – Excluding any new transactions, DRI now expects 2030 cash receipts to be at least as high as 2022 cash receipts – – Extends DRI’s overall portfolio duration to over 10 years – TORONTO, March 8, 2023 /CNW/ – DRI Healthcare […]

DRI Healthcare Trust Reports Fourth Quarter and Fiscal 2022 Results

– 2022 deployment of US$281 million continues to validate growth strategy – – Continued strong performance of existing assets and financial results – TORONTO, March 1, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022. […]

DRI Healthcare Trust Announces US$95 million Private Placement of Preferred Securities and Increased Deployment Target

– Provides additional capital to fund biopharmaceutical research, driving value for DRI’s unitholders and partners –  TORONTO, Feb. 8, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today that it has completed a private placement of US$95 million of preferred securities (the “Private Placement”) to an investor group that […]

DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of Omidria® for Intracameral Use During Cataract Surgery or Intraocular Lens Replacement

– Transaction adds a well-established ophthalmology product that generates substantial near-term cash flows, with long-term structural growth anticipated – – Third transaction of 2022 with US$184.5 million deployed YTD – – DRI to hold conference call to provide business update at 10:00 am ET this morning – TORONTO, Oct. 3, 2022 /CNW/ – DRI Healthcare […]